1-2 of 2
Fabian Acker
Close
Sort by
Journal Articles

Polatuzumab Vedotin in Relapsed and Refractory (r/r) Large B-Cell Lymphoma (LBCL): Real-World Data of the German National Compassionate Use Program (CUP)

Nora Liebers, MD, Johannes Duell, MD, Daniel Nörenberg, MD, Eva Kaebisch, MD, Andrea Kerkhoff, MD, Fabian Acker, MD, Stephan Fuhrmann, MD, Corinna Leng, MD PhD, Manfred Welslau, MD, Jens Chemnitz, MD, Jan Moritz Middeke, MD, Thomas Weber, MD, Ralf Ulrich Trappe, MD, Roald Pfannes, MD, Ruediger Liersch, MD, Christian Spoer, MD, Niklas Gebauer, MD, Stefan Fuxius, MD, Léandra Caillé, Christiane Pott, MD PhD, Christian Koenecke, MD, Udo Holtick, Thomas Geer, MD, Ulrich Keller, MD, Rainer Claus, MD, Dimitrios Mougiakakos, MD, Stephanie Mayer, MD, Andreas Hüttmann, MD, Arne Trummer, MD, Gerald Wulf, MD, Uta Brunnberg, MD, Lars Bullinger, MD, Georg Hess, MD, Carsten Mueller-Tidow, MD, Bertram Glass, MD, Georg Lenz, Peter Dreger, MD, Sascha Dietrich, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 11–13.
https://doi.org/10.1182/blood-2020-136539
Published: 2020
Journal Articles

Optimizing 25-OH-Vitamin D3 Serum Levels for Rituximab- and Obinutuzumab-Mediated Antibody-Dependent Cellular Cytotoxicity

Joerg Thomas Bittenbring, MD, Michael Pfreundschuh, MD, Fabian Acker, Frank Neumann, PhD
Journal: Blood
Blood (2015) 126 (23): 2734.
https://doi.org/10.1182/blood.V126.23.2734.2734
Published: 2015